Chiusura precedente | 23,77 |
Aperto | 24,95 |
Denaro | 0,00 x 0 |
Domanda | 0,00 x 0 |
Min-Max giorno | 23,33 - 24,95 |
Intervallo di 52 settimane | 7,38 - 34,12 |
Volume | |
Media Volume | 12.971 |
Capitalizzazione | 56,759M |
Beta (mensile su 5 anni) | 0,52 |
Rapporto PE (ttm) | N/D |
EPS (ttm) | -8,72 |
Prossima data utili | 09 ago 2024 - 13 ago 2024 |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | N/D |
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the first half of 2023, we made further progress in the development of cadisegliatin as an ad
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), announced today that Cantex Pharmaceuticals, Inc. recently obtained an exclusive worldwide license